<DOC>
	<DOCNO>NCT00559299</DOCNO>
	<brief_summary>The purpose study determine safety tolerability new drug , GSK163090 , develop treatment depression anxiety disorder .</brief_summary>
	<brief_title>Patient Tolerability Study GSK163090</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Male female subject age 18 65 year psychiatric diagnosis MDE associate MDD accord DSMIVTR ( 296.2/296.3 ) whose symptom consider mild moderate take antidepressant medication time screen least 4 week prior randomisation . If female , subject eligible enter participate study lactating : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal [ define one year without menses woman &gt; 45 year age ] ) ; surgically sterile [ via hysterectomy and/or removal ovary ] , 2 . Childbearing potential , negative pregnancy test screen baseline ( prior investigational product administration ) , agree acceptable method contraception Body weight â‰¥ 50 kg body mass index ( BMI ) 18.5 35.0 kg/m2 inclusive . Capable give informed consent comply study requirement timetable . Subjects HAMD17 score &gt; 18 &lt; 25 screen baseline . The subject must able read , comprehend record information . Nonsmoker light ( &lt; 10 cigarette per day ) smoker . Agree abstain alcohol 24 hour prior start dose collection final pharmacokinetic sample . Subjects whose symptom MDE well account another diagnosis . As result medical interview , physical examination screen investigation physician responsible considers subject unfit study . The subject history drug reaction allergy opinion physician responsible contraindicates participation study . The subject currently participate participate clinical trial new chemical entity investigational drug previous 2 month . In addition , subject participate clinical trial 3 new chemical entity past 12 month . The subject screening ECG parameter outside range define protocol The subject pulse rate &lt; 45 &gt; 100 bpm and/or systolic blood pressure &gt; 150 and/or &lt; 90 and/or diastolic blood pressure &gt; 90 &lt; 50 . History long QT syndrome ( personal family ) cardiac conduction disorder , clinically significant cardiac disease . The subject liver function test ( LFT ) elevate &gt; 1.5 time reference range prestudy screen remain elevated repeat LFT . Any clinically significant laboratory abnormality . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John'sWort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator sponsor medication interfere study procedure compromise subject safety . Use monoamine oxidase inhibitor ( MAOI ) linezolid ( antibiotic ) 1 month prior first dose study medication . Abuse alcohol define average weekly intake great 21 unit male 14 unit female average daily intake great 3 unit male 2 unit female . 1 unit equivalent halfpint ( 220mL ) beer 1 ( 25ml ) measure spirit 1 glass ( 125ml ) wine . Consumption grapefruit juice grapefruit within 7 day prior first dose study medication collection last PK sample . The subject unable abstain strenuous physical activity 48 h prior screen follow 48 h prior 48 h treatment period . Where participation study would result donation blood excess 500 mL within 90 day period An unwillingness male subject abstain , use condom , sexual intercourse pregnant lactate woman time first dose study medication 90 day follow administration last dose study medication OR An unwillingness male subject use condom/spermicide addition female partner use another form contraception IUD , oral contraceptive , injectable progesterone , subdermal implant tubal ligation woman could become pregnant time first dose study medication 90 day follow administration last dose study medication . Current recent ( within one year ) gastrointestinal disease ; history malabsorption , esophageal reflux , irritable bowel syndrome ; frequent ( week ) occurrence heartburn ; surgical intervention ( e.g. , cholecystectomy ) would expect influence absorption drug . Subjects , investigator 's judgement , pose homicidal serious suicidal risk , make suicide attempt within 6 month precede screen ever homicidal . The subject history clinically significant abnormality neurological system ( include dementia cognitive disorder significant head injury ) history seizure ( exclude febrile seizure ) . The subject test positive hepatitis C antibody hepatitis B surface antigen . The subject test positive HIV . The subject past history drug abuse dependence accord DSMIV TR criterion within past 12 month test positive urine drug abuse prestudy screening . The subject history serotonin syndrome investigator 's judgement , history clinical significant intolerance SSRIs . Subjects history migraine headaches respond treatment triptan medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>163090</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>MDD</keyword>
	<keyword>Depression</keyword>
	<keyword>Tolerability</keyword>
	<keyword>MDE</keyword>
</DOC>